# OnCo record silexion-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/silexion-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "silexion-therapeutics" ;
  schema:name "Silexion Therapeutics"@en ;
  schema:alternateName "Silexion Therapeutics Corp"@en, "Silexion Therapeutics Ltd."@en ;
  schema:description "Silexion Therapeutics is an Israeli company making a gene-silencing medicine, SIL204, that stops cancer cells making the faulty KRAS protein. A larger trial in pancreatic cancer that has spread locally began in Israel in July 2026."@en ;
  schema:url <https://onco.cc/companies/silexion-therapeutics/>, <https://www.silexion.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/2022416/000117891326004003/zk2635896.htm>, <https://www.silexion.com/> ;
  schema:addressCountry "IL" ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/antisense-sirna/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/sil204/> .